Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
COGT Cogent Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: COGT
Price (delayed)
$5.64
Market cap
$642.15M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.84
Enterprise value
$533.24M
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed
Highlights
The company's debt fell by 8% YoY and by 2.2% QoQ
The EPS rose by 5% QoQ
Cogent Biosciences's quick ratio has plunged by 58% YoY and by 3.3% from the previous quarter
The company's equity fell by 48% YoY and by 15% QoQ
Key stats
What are the main financial stats of COGT
Market
Valuations
Earnings
Shares outstanding
113.86M
Market cap
$642.15M
Enterprise value
$533.24M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.93
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$288.47M
Net income
-$269.5M
EBIT
-$269.5M
EBITDA
-$265.07M
Free cash flow
-$222.82M
Per share
Balance sheet
Liquidity
EPS
-$1.84
EPS diluted
-$1.84
Free cash flow per share
-$1.97
Book value per share
$1.92
Revenue per share
$0
TBVPS
$2.5
Total assets
$283.8M
Total liabilities
$64.8M
Debt
$17.09M
Equity
$219M
Working capital
$203.57M
Debt to equity
0.08
Current ratio
5.13
Quick ratio
4.98
Net debt/EBITDA
0.41
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-75.6%
Return on equity
-92.7%
Return on invested capital
-121.3%
Return on capital employed
-114.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COGT stock price
How has the Cogent Biosciences stock price performed over time
Intraday
-2.59%
1 week
15.57%
1 month
-3.92%
1 year
-35.91%
YTD
-27.69%
QTD
-5.84%
Financial performance
How have Cogent Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$288.47M
Net income
-$269.5M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 27% YoY and by 5% QoQ
COGT's operating income is down by 27% year-on-year and by 4.5% since the previous quarter
Price vs fundamentals
How does COGT's price correlate with its fundamentals
Growth
What is Cogent Biosciences's growth rate over time
Valuation
What is Cogent Biosciences stock price valuation
P/E
N/A
P/B
2.93
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 5% QoQ
The company's equity fell by 48% YoY and by 15% QoQ
The P/B is 37% above the 5-year quarterly average of 2.2 but 2.9% below the last 4 quarters average of 3.1
Efficiency
How efficient is Cogent Biosciences business performance
The company's return on equity fell by 46% YoY and by 24% QoQ
The ROA has contracted by 37% YoY and by 19% from the previous quarter
COGT's return on invested capital is down by 30% year-on-year and by 19% since the previous quarter
Dividends
What is COGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COGT.
Financial health
How did Cogent Biosciences financials performed over time
Cogent Biosciences's quick ratio has plunged by 58% YoY and by 3.3% from the previous quarter
COGT's current ratio has dropped by 57% year-on-year and by 3.6% since the previous quarter
The company's debt is 92% lower than its equity
Cogent Biosciences's debt to equity has surged by 100% YoY and by 14% QoQ
The company's equity fell by 48% YoY and by 15% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.